FAQ's

CosmeRNA is a topical cosmetic solution designed to support scalp care in individuals with androgenetic alopecia (AGA)-related concerns.
It focuses on localized modulation of androgen receptor (AR)-related pathways within the hair follicle environment, without systemic hormone involvement.
This localized, non-systemic approach differentiates CosmeRNA from conventional strategies based on systemic DHT modulation.

SAMiRNA™ is a patented next-generation siRNA platform, structurally distinct from conventional siRNA systems.
It consists of a dual-conjugated DNA/RNA heteroduplex that self-assembles into micellar nanoparticles in aqueous conditions, without the use of cationic lipids.
Designed for localized delivery, SAMiRNA™ supports minimized innate immune stimulation.
The resulting nanoparticles are typically <100 nm in size with near-neutral charge, characteristics considered favorable for follicular delivery.

SAMiRNA™-AR68 is the active component of CosmeRNA, designed to locally target androgen receptor (AR)-related pathways in the scalp.
It combines the SAMiRNA™ molecular construct with AR68, an AR-targeting RNA sequence selected through internal screening.
AR68 was identified as the lead candidate based on its favorable targeting profile within the SAMiRNA™ framework.
In this design, SAMiRNA™ defines the delivery construct, while AR68 represents the selected AR-targeting sequence.

As a topical cosmetic formulation designed for localized scalp application with minimal systemic exposure, conventional systemic half-life concepts are not directly applicable to CosmeRNA.
Human application studies have demonstrated favorable safety and tolerability, with no clinically significant adverse reactions observed.
Studies evaluating systemic exposure and follicular retention are ongoing to better characterize local persistence and clearance dynamics.

Conventional drug-based therapies (e.g., finasteride) typically require continuous use, with effects diminishing upon discontinuation.
CosmeRNA, based on an RNA-based approach, follows a distinct mechanism, with effects observed to decline more gradually after cessation.
In a 6-month randomized, double-blind, placebo-controlled study in European subjects, sustained effects were observed following treatment (see Table 2).
These findings suggest a different pattern of durability compared with conventional drug-based therapies.

Unlike conventional products, CosmeRNA is based on a molecularly designed RNA technology.
It incorporates a delivery system intended for localized application to the hair follicle area,
with a clearly defined active component.
This distinguishes CosmeRNA from standard hair or scalp products,
which typically rely on broader, non-targeted cosmetic approaches.

CosmeRNA Intensive is suitable for individuals experiencing hair thinning or weakened hair,
as well as those seeking supportive scalp care.

It may be considered for patients with concerns about scalp and hair condition,
those requiring low-irritation formulations,
or those wishing to maintain hair health alongside existing therapies.

Its clinical rationale includes early-stage care, ease of topical use,
and compatibility with ongoing treatment approaches.

Yes. CosmeRNA has been evaluated in both male and female populations.

In clinical studies, improvements in hair density, thickness, and scalp condition were observed,
including in female-only cohorts.

These findings support its use in both men and women.

CosmeRNA is classified as a cosmetic product.
It may be considered for adolescents, taking into account individual scalp condition and sensitivity.
Its low-irritation formulation is designed to support tolerability, including for sensitive scalp types.

CosmeRNA has undergone dermatological safety testing and is formulated without silicones or artificial colorants.

It may be considered for sensitive scalp conditions, although individual responses may vary, and a preliminary patch test is recommended.

Use on compromised scalp areas should be approached with caution, and application on areas with active inflammation or lesions should be avoided.

CosmeRNA is designed for sustained activity at the scalp following a single application.
In human studies evaluating different application intervals, weekly use during the initial phase (approximately 3 months) was associated with maintained improvements in scalp and hair parameters.
For maintenance, less frequent use (e.g., every 2 weeks) may be considered, based on study findings.

Continuous use may be considered to support ongoing scalp and follicular health.
The optimal application schedule can be adjusted based on clinician judgment and individual patient needs.

Scalp and hair condition are influenced by multiple factors, including lifestyle, stress, and hormonal changes.

If use is discontinued, the condition may gradually return toward its previous state.
Consistent use may help support maintenance of scalp condition over time.

A stepwise protocol may be considered:

Initial phase: Weekly in-clinic application for 4–8 weeks
Stabilization phase: Extend interval to bi-weekly, based on response
Maintenance phase: Adjust frequency according to clinician assessment and patient condition

This approach allows for an initial period of intensive care, followed by flexible long-term management.

CosmeRNA should be applied to areas of hair thinning or reduced hair density,
such as the crown or vertex of the scalp.

Application may be focused on affected regions,
with the amount adjusted according to the size and distribution of the area.

CosmeRNA may be used alongside other scalp or hair treatments.

To support optimal activity, avoid shampooing or applying other scalp products
for at least 6 hours after application.

CosmeRNA should not be used during dyeing or perming procedures,
as chemical agents may affect formulation stability.

Use may be resumed once the scalp is fully dry and free from irritation.

Allow approximately 6 hours after application to support optimal activity.
Avoid shampooing or applying other scalp products during this period.
Do not apply to areas with wounds, inflammation, or irritation.

CosmeRNA Intensive has been evaluated in human clinical studies,
with findings indicating low irritation and good tolerability.

Dermatological testing (Dermatest, Germany) reported a sensitivity rating of 0.00.
No clinically significant adverse events were observed.

Routine monitoring for local reactions is recommended during use.
These data support its use in both male and female patients.

CosmeRNA is a cosmetic product applied topically.

However, its safety has not been formally evaluated in pregnant or breastfeeding women.

Given potential changes in skin sensitivity during these periods,
use should be approached with caution or avoided, and consultation with a healthcare professional is recommended if needed.

Use is generally recommended outside of pregnancy and breastfeeding periods.

CosmeRNA is formulated without fragrance, silicones, or added colorants to help minimize potential irritants.

It has undergone irritation testing on sensitive skin, with findings indicating good tolerability.
Individual responses may vary; patients with a history of allergies should review the full ingredient list and perform a patch test prior to use.

Use should be approached with caution in individuals with known sensitivities.

CosmeRNA may be incorporated into broader hair management strategies.
Combination approaches should be determined based on clinician judgment.

Application should begin only after complete wound healing has been confirmed.

A stepwise protocol may be considered:

Weeks 1–2: Weekly, clinic-based application
Weeks 3–8 (graft stabilization phase): Continue weekly application
From Month 3 (growth phase): Extend to bi-weekly application
After 6 months: Incorporate into long-term maintenance alongside other post-care treatments

Concurrent use with finasteride or other therapies may be considered based on clinician judgment.

CosmeRNA may be used alongside topical hair loss medications, such as minoxidil.
As a topical cosmetic formulation, no pharmacological interactions have been reported to date.
Decisions regarding timing, sequencing, and monitoring should be guided by the treating clinician.